Giverny Capital Asset Management, LLC, an investment management company, recently published its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The portfolio returned -3.39% in the quarter, compared to a -4.27% return for the S&P 500 Total Return Index. For the year ended March 31, 2025, the fund returned 1.75% compared to an 8.25% return for the Index during the same period. For more information on the fund’s best picks in 2025, please check its top five holdings.
In its first quarter 2025 investor letter, Giverny Capital Asset Management highlighted stocks such as Medpace Holdings, Inc. (NASDAQ:MEDP). Medpace Holdings, Inc. (NASDAQ:MEDP) is a clinical research-based drug and medical device development services provider. The one-month return of Medpace Holdings, Inc. (NASDAQ:MEDP) was -7.31%, and its shares lost 20.85% of their value over the last 52 weeks. On April 17, 2025, Medpace Holdings, Inc. (NASDAQ:MEDP) stock closed at $296.28 per share with a market capitalization of $8.96 billion.
Giverny Capital Asset Management stated the following regarding Medpace Holdings, Inc. (NASDAQ:MEDP) in its Q1 2025 investor letter:
“We added to existing positions in Medpace Holdings, Inc. (NASDAQ:MEDP) and Kinsale, both of which are now among our top 10 holdings. Medpace is a clinical research organization that helps emerging biopharma companies conduct trials on new compounds. I believe it is a world-class company with a great founder-CEO in August Troendle, but the current Food & Drug Administration leadership appears hostile to drug research. Medpace may see its growth slow for a time. Easing our pain somewhat, the company has a large cash position and a history of buying back its own stock during periods of weakness.”
A medical professional in a lab coat discussing with a colleague.
Medpace Holdings, Inc. (NASDAQ:MEDP) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held Medpace Holdings, Inc. (NASDAQ:MEDP) at the end of the fourth quarter which was 41 in the previous quarter. Medpace Holdings, Inc.’s (NASDAQ:MEDP) fourth quarter revenue was $536.6 million, up 7.7% year-over-year and full year 2024 revenue was $2.11 billion, up 11.8% from 2023. While we acknowledge the potential of Medpace Holdings, Inc. (NASDAQ:MEDP) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we covered Medpace Holdings, Inc. (NASDAQ:MEDP) and discussed Vulcan Value Partners, views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.